CN104147453A - Use of medicinal composition in preparation of erosive gastritis treatment medicines - Google Patents
Use of medicinal composition in preparation of erosive gastritis treatment medicines Download PDFInfo
- Publication number
- CN104147453A CN104147453A CN201410406425.2A CN201410406425A CN104147453A CN 104147453 A CN104147453 A CN 104147453A CN 201410406425 A CN201410406425 A CN 201410406425A CN 104147453 A CN104147453 A CN 104147453A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- erosive gastritis
- poria
- perillae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a use of a medicinal composition shown in the specification in the preparation of erosive gastritis treatment medicines. The medicinal composition is a preparation prepared by using the following raw medicines, by weight, 17-23 parts of Potentilla anserine L., 7-12 parts of Poria cocos, 5-9 parts of Capillary Wormwood Herb, 5-9 parts of Pogostemon cablin, 5-9 parts of raw malt, 3-7 parts of Cortex Magnoliae Officinalis, 3-7 parts of folium perillae and 3-7 parts of Caulis Perillae. The above medicine can effectively treat the erosive gastritis through a specific ratio of few medicines, and provides a new medicine use choice for the clinic treatment of the erosive gastritis.
Description
Technical field
The present invention relates to the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment erosive gastritis.
Background technology
Chronic erosive gastritis, claims again the indigestion symptoms such as general rarely seen glutted, the pantothenic acid after meal of gastritis verrucosa or varioliform gastritis, belch, irregularities stomachache.There are a plurality of excipuliforms in Stomach in Patients mucosa, expands folded shape or pimple sample protuberance, diameter 5～10mm, and the visible mucomembranous defect in top or umbilicus sample depression, there is erosion at center, and protuberance is many without blush around, but normal with the similar erythema of size, with gastric antrum, portion is common.The symptoms such as general rarely seen glutted, pantothenic acid after meal, belch, irregularities stomachache and dyspepsia.
The medicine of the above-mentioned disease of current treatment mostly is chemical drugs, and it is expensive, and side effect is large, and healing required time is long.Therefore, be badly in need of a kind of economical and practical, toxic and side effects is low, and can rapid healing the medicine of above-mentioned disease.
And Chinese medicine aspect treatment of chronic diseases one to all playing an important role.Report, also there is people to use Os Sepiae (life) 250g, Concha Arcae (calcined) 250g, Radix Et Rhizoma Rhei 200g, Radix Glycyrrhizae Preparata 200g, grind to the powder, boiled water is taken after mixing it with water after meal, each 15g, every day 3～4 times, be used for the treatment of peptic ulcer (Gu Linjiang, Cuttlefish Bone Powder for Peptic Ulcer, journal of shanghai Chinese medicine, 9 phases of calendar year 2001.Also there is people to treat peptic ulcer with Fructus Amomi Rotundus 10g, Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Herba Pogostemonis 15g, Herba Taraxaci 15g, Radix Ginseng 5g, Folium Perillae 10g, Semen Armeniacae Amarum 10g, Semen Coicis 20g, Herba Artemisiae Scopariae 15g, there is good therapeutic effect.Chinese Patent Application No.: 201310259917.9, disclose a kind of pharmaceutical composition for the treatment of peptic ulcer, its proportioning raw materials is as follows: Radix Rhodiolae 4.2-7.2 part, Poria 14-26 part, Herba Taraxaci 10.5-19.5 part, Herba Artemisiae Scopariae 10.5-19.5 part, Rhizoma Atractylodis Macrocephalae 10.5-19.5 part, Herba Pogostemonis 7-13 part, Fructus Hordei Germinatus 7-13 part, Fructus Amomi Rotundus 3.5-6.5 part.This prescription drug can effectively be treated gastric ulcer, duodenal ulcer and erosive gastritis.
Yet, current erosive gastritis patient One's name is legion, supply falls short of demand for market medicine, therefore, develops a kind of new pharmaceutical composition that can effectively treat erosive gastritis and seem particularly necessary.
Summary of the invention
The object of the present invention is to provide the purposes of a kind of pharmaceutical composition in the medicine of preparation treatment erosive gastritis.
The invention provides the purposes of pharmaceutical composition as follows in the medicine of preparation treatment erosive gastritis, described pharmaceutical composition is the preparation that the crude drug by following weight proportion is prepared from:
Radix potentillae anserinae 17-23 part, Poria 7-12 part, Herba Artemisiae Scopariae 5-9 part, Herba Pogostemonis 5-9 part, Fructus Hordei Germinatus 5-9 part, Cortex Magnoliae Officinalis 3-7 part, Folium Perillae 3-7 part, Caulis Perillae 3-7 part.
Further, it is the preparation that the crude drug by following weight proportion is prepared from:
Radix potentillae anserinae 19-21 part, Poria 9-11 part, Herba Artemisiae Scopariae 6-8 part, Herba Pogostemonis 6-8 part, Fructus Hordei Germinatus 6-8 part, Cortex Magnoliae Officinalis 4-6 part, Folium Perillae 4-6 part, Caulis Perillae 4-6 part.
Further, it is the preparation that the crude drug by following weight proportion is prepared from:
20 parts of Radix potentillae anserinae, 10 parts, Poria, 7 parts of Herba Artemisiae Scopariaes, 7 parts of Herba Pogostemonis, 7 parts of Fructus Hordei Germinatus, 5 parts of Cortex Magnoliae Officinalis, 5 parts of Folium Perillae, 5 parts of Caulis Perillaes.
The present invention studies discovery, and under this conditions of mixture ratios, its drug activity is significantly better than other proportionings, and curative effect is clear and definite.
Wherein, it is to be active component by the water of the crude drug of described weight proportion or extractive with organic solvent, adds the preparation that pharmaceutically acceptable adjuvant is prepared from.
Preparation of the present invention is oral formulations, as granule, tablet, powder, decoction, oral liquid, pill etc.
The present invention also provides the preparation method of above-mentioned pharmaceutical composition, and it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) crude drug is decocted with water to extraction, merge decocting liquid, add that pharmaceutically acceptable adjuvant or complementary composition are prepared into preparation.
In the present invention, Radix potentillae anserinae (formal name used at school: Potentilla anserina) be the plant of Rosaceae Potentilla.Perennial herb.Radix potentillae anserinae also claims Herba Herminii.Sweet, flat, fill blood, strengthening the spleen and stomach, promoting the production of body fluid to quench thirst, dampness removing.Be used for anemia after being ill, malnutrition, insufficiency of the spleen diarrhoea, rheumatic arthralgia.
Herba Artemisiae Scopariae is that the quadrate part dryly of feverfew Artemisia scoparia Waldst. et Kit. Artemisia scoparia Waldst.Et Kit. or Herba Artemisiae Scopariae Artemisia capillaries Thunb. divides.Bitter, pungent, be slightly cold, return spleen, stomach, liver, gallbladder meridian.Eliminating damp-heat, promoting the function of the gallbladder to alleviate jaundice.For jaundice oliguria, hygropyrexia heat-damp in summer, eczema pruritus.
Poria is the dry sclerotia of On Polyporaceae Poria Poria cocos (Schw.) Wolf.Sweet, light, flat.GUIXIN, lung, spleen, kidney channel.Promoting diuresis to eliminate damp pathogen, spleen invigorating, mind calming.For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia.
Herba Pogostemonis is that the quadrate part dryly of labiate Herba Pogostemonis Pogostemon cablin (Blanco) Benth. divides.Pungent, tepor.Return spleen, stomach, lung meridian.Eliminating turbid pathogen with aromatics, and middle preventing or arresting vomiting, deliver expelling summer-heat.For turbid damp obstructing in middle-JIAO, the vomiting of gastral cavity painful abdominal mass, heat-damp in summer exterior syndrome, hygropyrexia is from the beginning of, heating asthenia, uncomfortable in chestly do not relax, and cold-damp is closed summer-heat, and stomachache is vomited and diarrhoea, nasosinusitis headache.
Folium Perillae is the band branch tender leaf of Labiatae Perilla plant Folium Perillae, and Folium Perillae has expelling cold and relieving exterior syndrome, the effect of regulating the flow of QI to ease the stomach, and Folium Perillae cures mainly anemofrigid cold, headache, cough, distension and fullness of the chest and abdomen.
Caulis Perillae is the dry stem of labiate Folium Perillae Perilla frutescens (L.) Britt., regulating the flow of QI to ease the stomach, and pain relieving, antiabortive.Vexed for chest and diaphragm painful abdominal mass, gastralgia, belch vomiting, frequent fetal movement.
Medicine of the present invention is by specific consumption proportion, and flavour of a drug are less, can effectively treat erosive gastritis, for clinical treatment erosive gastritis provides a kind of new medication, selects.
The specific embodiment
The preparation of embodiment 1 medicine of the present invention
Get Radix potentillae anserinae 20g, Poria 10g, Herba Artemisiae Scopariae 7g, Herba Pogostemonis 7g, Fructus Hordei Germinatus 7g, Cortex Magnoliae Officinalis 5g, Folium Perillae 5g, Caulis Perillae 5g; Add 8 times of water gagings to decoct 3 times, each 10 minutes, filter, merge after decocting liquid, obtain medicine decoction of the present invention.
The preparation of embodiment 2 medicines of the present invention
Get Radix potentillae anserinae 20g, Poria 10g, Herba Artemisiae Scopariae 7g, Herba Pogostemonis 7g, Fructus Hordei Germinatus 7g, Cortex Magnoliae Officinalis 5g, Folium Perillae 5g, Caulis Perillae 5g; Decoct with water 3 times, add for the first time 10 times of water gagings and decoct 5 minutes, add for the second time 8 times of water gagings and decoct 10 minutes, add for the third time 8 times of water gagings and decoct 15 minutes, filter, merge after decocting liquid, concentrated, then add proper starch, and granulate, obtain medicinal granule of the present invention.
The preparation of embodiment 3 medicines of the present invention
Radix potentillae anserinae 20g, Poria 10g, Herba Artemisiae Scopariae 7g, Herba Pogostemonis 7g, Fructus Hordei Germinatus 7g, Cortex Magnoliae Officinalis 5g, Folium Perillae 5g, Caulis Perillae 5g; Get other flavour of a drug except Radix potentillae anserinae, first add 10 times of amount 70% alcoholic solution reflux, extract, 1 time, extract 1 hour, filter, filtrate for later use, filtering residue again water decocts 2 times, add 8 times of amounts of water at every turn, decoct 20 minutes at every turn, merge after ethanol extract and decocting liquid, concentrated, add again Radix potentillae anserinae powder, after granulation, then add appropriate magnesium stearate, tabletting, obtains medicinal tablet of the present invention.
By concrete test example, further show beneficial effect of the present invention below.
The treatment of test example 1 medicine of the present invention to chronic erosive gastritis
Chronic erosive gastritis diagnostic criteria: occur the indigestion symptoms such as glutted, acid regurgitation, belch, irregularities stomachache, melena appears in small number of patients; Endoscopy, visible gastric mucosa congestion and edema, some lamellar is rotten to the corn, the multiple ulcer differing in size, ulcer surface can have the fresh clot that goes out.Accept altogether 30 examples for medical treatment, endoscopy is confirmed as chronic erosive gastritis.
Therapeutic Method: get the decoction that embodiment 1 prepares, every bu is taken for 3 times, period in a medicine, avoids eating anything raw or cold, maror.
Criterion of cure: the indigestion symptoms such as acid regurgitation, stomachache disappear, endoscopy, rotten to the corn without point-like or lamellar, mucosa edema disappears, and gastric mucosa heals.By Therapeutic Method, take medicine continuously, treat 15～30 days, cure 30 examples, account for 100% of total case.Between the operating period, there are no patient, there is the feedback of toxicity, illustrate that drug safety of the present invention is better.
Model case 1
In certain, man, 22 years old, stomach felt there is feeling of repletion, obvious especially when rise morning, after meal or close on ante cibum and have belch phenomenon, the late into the night, wake up feeling stomach had a little burn feeling, anorexia, body weight obviously alleviates; Through gastroscopy, confirm as erosive gastritis.
By test example 1 method, take medicine after 7 days, feeling of repletion, belch phenomenon are alleviated, and after 20 days, it is suitable with normal period that appetite has recovered, swollen sense, belch phenomenon disappear, and treat after 30 days, through gastroscopy, ulcer surface heals, and conscious appetite, stomach feel good, and body weight is gone up.
The screening of test example 2 pharmaceutical compositions of the present invention
Get SD rat, male and female half and half fasting is after 12 hours, rats by intraperitoneal injection 3% is anaesthetized without barbital sodium, with the alcohol cotton stick skin of sterilizing, cut abdominal cavity open, in glandular stomach portion, antetheca hole body intersection serosal surface sticks the circular filter paper 30s that soaks into glacial acetic acid, diameter 5mm, repeat 3 times, close abdomen sewing-up cut, be coated with penicillin.Postoperative routine feeding, the 4th day by animal random packet, model group gavage 10mlkg
-1distilled water, positive drug ranitidine group gavage 30mgkg
-1, each screening group of the present invention 10g crude drug/kg body weight.The 2nd day after grouping starts gastric infusion, administration every day 1 time, and dosage is 10mlkg
-1, continuous 5 days, last administration is de-cervical vertebra execution animal after 12 hours, cut open the belly and get stomach, with normal saline, wash gastric content, stomach is fixed in 10% formaldehyde, after 15 minutes, stomach is lain on glass surface ware, under magnifier, with slide gauge, measure major diameter and the minor axis of ulcer surface, and calculate ulcer surface.
Calculate ulcer inhibition rate: ulcer inhibition rate=(matched group ulcer area-administration group ulcer area)/matched group ulcer area x100%, observes ulcer healing degree.
Experimental result is in Table 1.
Table 1
Note: compare with model group, * is p < 0.05, and * * is p < 0.01;
Wherein, the compatibility of each screening group is as follows:
Group 1: Radix potentillae anserinae 5g, Poria 10g, Herba Artemisiae Scopariae 10g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Cortex Magnoliae Officinalis 8g, Folium Perillae 8g, Caulis Perillae 8g;
Group 2: Radix potentillae anserinae 10g, Poria 8g, Herba Artemisiae Scopariae 8g, Herba Pogostemonis 8g, Fructus Hordei Germinatus 8g, Cortex Magnoliae Officinalis 5g, Folium Perillae 5g, Caulis Perillae 5g;
Group 3: Radix potentillae anserinae 15g, Poria 7g, Herba Artemisiae Scopariae 7g, Herba Pogostemonis 7g, Fructus Hordei Germinatus 7g, Cortex Magnoliae Officinalis 5g, Folium Perillae 5g, Caulis Perillae 5g;
Group 4: Radix potentillae anserinae 20g, Poria 10g, Herba Artemisiae Scopariae 7g, Herba Pogostemonis 7g, Fructus Hordei Germinatus 7g, Cortex Magnoliae Officinalis 5g, Folium Perillae 5g, Caulis Perillae 5g.
The above-mentioned compound recipe of respectively organizing, flavour of a drug are identical, but medical material consumption proportion difference has appreciable impact to the drug activity of compound recipe: group 1-3, all the gastric ulcer of animal pattern is had to certain inhibitory action, but it is not remarkable to suppress activity; Yet the prescription proportioning of employing group 4, can significantly improve the therapeutic activity of compound medicine, is significantly better than other each proportioning groups, therefore, the prescription proportioning of preferred group 4 of the present invention.Above-mentioned test shows, pharmaceutical composition of the present invention, under specific proportioning, has been brought into play synergistic function.
The therapeutical effect of test example 3 pharmaceutical composition of the present invention to acetic acid type gastric ulcer
Get SD rat, fasting is after 12 hours, and rats by intraperitoneal injection 3% is anaesthetized without barbital sodium, with the alcohol cotton stick skin of sterilizing, cut abdominal cavity open, in glandular stomach portion, antetheca hole body intersection serosal surface sticks the circular filter paper 30s that soaks into glacial acetic acid, diameter 5mm, repeat 3 times, close abdomen sewing-up cut, be coated with penicillin.Postoperative routine feeding, is divided into 6 groups at random by animal on the 4th day, and 10 every group, male and female half and half, are respectively model group (10mlkg
-1distilled water), pharmaceutical composition of the present invention senior middle school low dose group (be followed successively by 10,20,40g crude drug/kg body weight), contrast groups A (10g crude drug/kg body weight), contrast groups B (10g crude drug/kg body weight), positive drug ranitidine group (30mgkg
-1).The 2nd day after grouping starts gastric infusion, administration every day 1 time, and dosage is 10mlkg
-1, continuous 5 days, last administration is de-cervical vertebra execution animal after 12 hours, cut open the belly and get stomach, with normal saline, wash gastric content, stomach is fixed in 10% formaldehyde, after 15 minutes, stomach is lain on glass surface ware, under magnifier, with slide gauge, measure major diameter and the minor axis of ulcer surface, and calculate ulcer surface.
Calculate ulcer inhibition rate: ulcer inhibition rate=(matched group ulcer area-administration group ulcer area)/matched group ulcer area x100%, observes ulcer healing degree.
Pharmaceutical composition of the present invention is prepared by embodiment 1;
The preparation method of contrast groups A medicine is as follows:
Get Fructus Amomi Rotundus 10g, Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Herba Pogostemonis 15g, Herba Taraxaci 15g, Radix Ginseng 5g, Folium Perillae 10g, Semen Armeniacae Amarum 10g, Semen Coicis 20g, Herba Artemisiae Scopariae 15g; Add 8 times of water gagings to decoct 3 times, each 10 minutes, filter, merge decocting liquid, obtain contrast groups A decoction.
The preparation method of contrast groups B medicine is as follows:
Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g.Add 8 times of water gagings to decoct 3 times, each 10 minutes, filter, merge decocting liquid, obtain contrast groups B decoction.
Experimental result is in Table 2.
Table 2
Note: compare with model group, * is p < 0.05, and * * is p < 0.01; A compares with contrast groups, and Δ is p < 0.05, and Δ Δ is p < 0.01; B compares with contrast groups, and a is p < 0.05.
As shown in Table 2, pharmaceutical composition of the present invention, can effectively treat gastric ulcer, and meanwhile, A compares with contrast groups, and the drug activity of pharmaceutical composition of the present invention under Isodose is obviously better than contrast groups A (p < 0.05).B compares with contrast groups, and the drug activity under Isodose is suitable.
In sum, compatibility of drugs of the present invention is precise and appropriate, and flavour of a drug are less, can effectively treat erosive gastritis, for clinical treatment erosive gastritis provides a kind of new medication, selects.
Claims (5)
1. the purposes of pharmaceutical composition as follows in the medicine of preparation treatment erosive gastritis, described pharmaceutical composition is the preparation that the crude drug by following weight proportion is prepared from:
Radix potentillae anserinae 17-23 part, Poria 7-12 part, Herba Artemisiae Scopariae 5-9 part, Herba Pogostemonis 5-9 part, Fructus Hordei Germinatus 5-9 part, Cortex Magnoliae Officinalis 3-7 part, Folium Perillae 3-7 part, Caulis Perillae 3-7 part.
2. compound according to claim 1, is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
Radix potentillae anserinae 19-21 part, Poria 9-11 part, Herba Artemisiae Scopariae 6-8 part, Herba Pogostemonis 6-8 part, Fructus Hordei Germinatus 6-8 part, Cortex Magnoliae Officinalis 4-6 part, Folium Perillae 4-6 part, Caulis Perillae 4-6 part.
3. compound according to claim 2, is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
20 parts of Radix potentillae anserinae, 10 parts, Poria, 7 parts of Herba Artemisiae Scopariaes, 7 parts of Herba Pogostemonis, 7 parts of Fructus Hordei Germinatus, 5 parts of Cortex Magnoliae Officinalis, 5 parts of Folium Perillae, 5 parts of Caulis Perillaes.
4. according to the compound described in claim 1-3, it is characterized in that: it is to be active component by the water of the crude drug of described weight proportion or extractive with organic solvent, adds the preparation that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
5. according to the preparation described in claim 1-4, it is characterized in that: described preparation is oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410406425.2A CN104147453A (en) | 2014-08-12 | 2014-08-12 | Use of medicinal composition in preparation of erosive gastritis treatment medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410406425.2A CN104147453A (en) | 2014-08-12 | 2014-08-12 | Use of medicinal composition in preparation of erosive gastritis treatment medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104147453A true CN104147453A (en) | 2014-11-19 |
Family
ID=51873216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410406425.2A Pending CN104147453A (en) | 2014-08-12 | 2014-08-12 | Use of medicinal composition in preparation of erosive gastritis treatment medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104147453A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138551A (en) * | 2014-08-12 | 2014-11-12 | 徐继锋 | Application of pharmaceutical composition in preparation of medicaments for treating duodenal ulcer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285309A (en) * | 2013-06-26 | 2013-09-11 | 中国科学院西北高原生物研究所 | Rhodiola rosea compound composition for treating peptic ulcer |
-
2014
- 2014-08-12 CN CN201410406425.2A patent/CN104147453A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285309A (en) * | 2013-06-26 | 2013-09-11 | 中国科学院西北高原生物研究所 | Rhodiola rosea compound composition for treating peptic ulcer |
Non-Patent Citations (2)
| Title |
|---|
| 毛欣欣等: "隆起糜烂性胃炎病因及发病机制研究现况", 《辽宁中医药大学学报》 * |
| 陈超等: "化湿法治疗慢性糜烂性胃炎体会", 《山东中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138551A (en) * | 2014-08-12 | 2014-11-12 | 徐继锋 | Application of pharmaceutical composition in preparation of medicaments for treating duodenal ulcer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103272169B (en) | Application of rhodiola rosea compound composite in treating erosive gastritis | |
| CN103285309B (en) | Rhodiola rosea compound composition for treating peptic ulcer | |
| CN104138550A (en) | Preparation method of medicine for treating peptic ulcers | |
| CN103285310B (en) | Use of rhodiola rosea compound composition in preparing medicine for curing gastric ulcer | |
| CN107362213B (en) | Composition with bowel relaxing function and preparation method thereof | |
| CN103272170B (en) | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer | |
| CN104666579A (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method of traditional Chinese medicine composition | |
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN104138553A (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN102949698A (en) | Medicine for treating uterine myoma and preparation method thereof | |
| CN104138551A (en) | Application of pharmaceutical composition in preparation of medicaments for treating duodenal ulcer | |
| CN104147453A (en) | Use of medicinal composition in preparation of erosive gastritis treatment medicines | |
| CN103495103B (en) | Medicament for promoting digestion and strengthening spleen | |
| CN102430073B (en) | Medicinal composition for treating peptic ulcer | |
| CN104138552A (en) | Application of pharmaceutical composition in preparation of medicaments for treating gastric ulcer | |
| CN105214035A (en) | One treats peptic ulcer tablet and preparation method thereof | |
| CN105250397A (en) | Spirulina traditional Chinese medicine composition | |
| CN104435641A (en) | Traditional Chinese medicine preparation for treating hyperthyroidism | |
| CN104666999A (en) | Traditional Chinese medicine formula capable of reducing blood pressure | |
| CN104740405B (en) | A kind of Chinese medicine preparation and preparation method for treating anaphylactoid purpura renal damage | |
| CN103656534A (en) | Traditional Chinese medicine for treating oesophagitis | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN102416122B (en) | Application of medicinal composition in preparation of medicaments for treating duodenal ulcer | |
| CN105250951A (en) | Preparing method for medicine for treating peptic ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141119 |
|
| WD01 | Invention patent application deemed withdrawn after publication |